Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Treat-to-Target in Axial Spondyloarthritis (TRACE)
NCT03639740Phase 4Unknown
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS). Status: unknown.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03639740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639740.